Patient or population: migraine Intervention: prophylaxis with amitriptyline Comparison: placebo | |||||
---|---|---|---|---|---|
Outcomes | № of participants (studies) | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effectsa | |
Risk with placebo | Risk difference with Amitriptyline | ||||
50% or more reduction in monthly migraine days | 389 (3 RCTs) | Moderate (downgraded due to risk of bias) | RR 1.60 (1.17 to 2.19) | 275 per 1,000 | 165 more per 1,000 (47 more to 327 more) |
Monthly migraine days | 118 (1 RCT) | High | - | NA | MD 1.2 migraine days fewer (2.1 fewer to 0.3 fewer) |
Adverse events leading to discontinuation | 507 (2 RCTs) | Moderate (downgraded due to risk of bias) | RD 0.05 (0.01 to 0.10) | 0 per 1,000 | 50 more per 1,000 (10 more to 100 more) |